Senores Pharmaceuticals Limited has entered into the Share Purchase Agreement (SPA) with one of the shareholders (Public Category) of Havix Group Inc. D/B/A Aavis Pharmaceuticals (Havix) for acquisition of 6,730 equity shares of Havix i.e. 2.97% of the total paid up share capital of Havix and subject to the terms and conditions as mentioned in the SPA.

Further, post the aforesaid acquisition the aggregate shareholding of the company (along with the shareholding of its wholly owned subsidiary - Senores Pharmaceuticals Inc.) in Havix will increase from 70.07% to 73.04%.

Havix was incorporated under the laws of the State of Delaware on February 17, 2015. Havix is a US based company engaged in the business of developing, manufacturing and supplying of various finished formulations. The turnover of Havix for the financial year ended March 31, 2025 was US$ 19,869,291.